Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMA402 + chemotherapy
- Development stage
- Unknown
- Lead developer
- Immatics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
IMA402 + chemotherapy is an investigational combination therapy being evaluated for the treatment of recurrent and/or refractory solid tumors. IMA402 is a next-generation, half-life extended bispecific T Cell-Engaging Receptor (TCER®) molecule developed by Immatics. It is designed to target a peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma) presented by HLA-A*02:01. The TCER® molecule consists of a high-affinity T-cell receptor (TCR) domain that binds the PRAME-HLA complex and an anti-CD3 effector domain that recruits and activates T cells to eliminate cancer cells. The combination with chemotherapy is intended to potentially enhance anti-tumor activity in patients with PRAME-expressing solid tumors, such as cutaneous and uveal melanoma, ovarian cancer, and synovial sarcoma.
- Other names
- IMA402 plus chemotherapyIMA-402 plus chemotherapyIMA 402 plus chemotherapy
02
Targets
CD3 (T-cell surface glycoprotein CD3)PRAME/HLA-A*02:01 (Preferentially expressed antigen in melanoma (PRAME) peptide presented by HLA-A*02:01)
Beyond the preview
Go deeper on IMA402 + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMA402 + chemotherapy.